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INNOVATIONS AND COMPETITIVE ADVANTAGE 





Growing competition and market dynamics are some of the main features of mod-
ern economics so resources such as knowledge and human capital are increasingly 
emerging. The main aim of this paper is to examine the effects and consequences of 
innovations in pharmaceutical companies in Croatia, their advantages and disad-
vantages, the importance of innovation as key drivers of the business, problems they 
encounter when introducing innovations regarding acceptance and adaptation to 
new changes in the company. For the purpose of data collection, interviews were 
conducted with representatives of companies that are performing leading functions 
and therefore they provided insight into the main differences that make these compa-
nies stand out among the competition as well as the characteristics of those innova-
tions that make them unique on the market. Interviews were conducted with a small 
number of companies, which is why generalization can result in a high degree of bias. 
Nevertheless, insight has been provided into the correlation regarding investment, 
innovation, and the benefits they provide for the employees, industry, and society. 
The differences found can serve as a basis for further research and improvement of 
the current practice within the industry.
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1. INTRODUCTION
The competitiveness of enterprises must be based on the standards of the glob-
al market and the limits of productivity of the most successful enterprises at 
the world level since the domestic and local markets cannot be protected by 
isolation mechanisms from competitive pressures that exist beyond borders. 
It is only through a systematic innovative activity that it is possible to differ-
entiate a product and make it more attractive to customers.1 Technology and 
innovation are some of the key determinants of long-term per capita produc-
tivity and growth. In a global economy characterized by growing competition 
and geographically divided and mobile manufacturing activities, knowledge 
and innovation are becoming increasingly important sources of sustainable 
competitive advantage.2 The basis of sustainable competitive advantage is 
invisible resources because invisible resources are specific to the enterprise 
that owns them, but also because such resources are not easily imitated.3 As a 
result, technological and innovation policies are becoming a major objective 
of economic policy. Their role is even more prominent thanks to modern pro-
cesses such as increased global competitiveness and shortening the product 
life cycle. Investigating the effects and consequences of innovations in phar-
maceutical companies operating on the territory of the Republic of Croatia 
can provide insight into their advantages and disadvantages, the intensity of 
their importance to innovations as key drivers of the business, the problems 
they face in introducing innovations in terms of accepting and adapting to new 
ones, the changes in the company and a reflection of these innovations on the 
overall business activities. Furthermore, once the difficulties and obstacles 
have been identified, it is possible in the future to work on how they can be 
more easily mitigated and brought to the highest productivity point.
1  Heraty, N., Morley, M.J.: Management Development in Ireland: The New Organizational 
Wealth, Journal of Management Development, 22 (1) 2003, pp. 60-82.
2  Nolan A., D. Pilat: Benefitting from the Next Product revolution, OECD Insights, 2016 
3  Wong, Y. C., Karia, N.: Explaining the competitive advantage of logistics service provid-
ers: A resource-based view approach, International Journal of Production Economics, 128 (1) 
2010, pp. 51-67.
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2. THE THEORETICAL FRAMEWORK
2.1. INNOVATION AS THE BASIS OF ACTION OF COMPETITIVE 
ENTERPRISES
The definitions of innovation are different, but most of them emphasize new 
approaches or products as a result of significant improvements, including the 
generation, development, and implementation of new and better ideas regard-
ing production, products, rules, strategies, services, procedures, models and 
other solutions that create added social and economic value.4 The key distinc-
tion between the concepts of invention and innovation is crucial. Definitions 
may differ, but they all share a common point, which is to emphasize the im-
portance of completing development and the practical use of new knowledge, 
not just invention or invention per se. The invention is only the first step in 
realizing and implementing a good idea, and in order to become an innova-
tion, it must be molded into the product or service that consumers want and 
that needs to be commercialized.5 On the other hand, innovation is any idea, 
behavior, or product that is qualitatively different from the existing and previ-
ous forms and as such entails the successful conceptualization and marketing 
of new products or services.6 Building a sustainable advantage in a highly 
competitive environment is a difficult task and may result in the irrational use 
of already scarce resources.7 Competitive advantage ensures the company’s 
financial survival. The basis of sustainable competitive advantage is invisible 
resources because invisible resources are specific to the enterprise that owns 
them and because they cannot be easily imitated.8 Innovation is the process 
of generating creative ideas and turning them into useful product, service, or 
method.9 On the other hand, innovation is the process by which companies use 
4  Crespell, P., Hansen, E.: Managing for innovation: Insights into a successful company, 
Forest products journal, 58(9) 2008, pp. 6-17.
5  Tidd J., Bessant J.: Managing innovation: Integrating technological, market and organi-
zational change. Chichester: J. Wiley and Son, 2009.
6  Cakar, N. D., Erturk, A.: Comparing Innovation Capability of Small and Medium-Sized 
Enterprises: Examining the Effects of Organizational Culture and Empowerment, Journal of 
Small Business Management, 48 (3) 2010, pp. 325-359. 
7  D’Aveni, D. A.: Beating the Commodity Trap: How to Maximize Your Competitive Posi-
tion and Increase Your Pricing Power. Boston: Harward Business Press, 2010
8  Wong, Y. C., Karia, N.: Explaining the competitive advantage of logistics service provid-
ers: A resource-based view approach, International Journal of Production Economics, 128 (1) 
2010, pp. 51-67.
9  Boddy, D.: Management: an introduction. Pearson Education, 2008
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their skills and resources to develop new products and services or to develop 
new production and service systems to better meet customer needs.10 Some 
authors define innovation as key, non-routine, and intermittent organizational 
changes that embody new ideas that are not in line with the company’s cur-
rent business concept.11 With technological breakthroughs and innovations, 
the emphasis is on technology that is new or improved from previous ver-
sions. They may include new products/services, new processes (or enhanced 
processes). The link between new products/services and new processes is cru-
cial.12 It is important to note that technological innovation can create the need 
for non-technological innovation in the enterprise. Non-technological innova-
tions stimulate and enable the development and introduction of technological 
innovations, thereby generating higher revenues as well as better utilization of 
innovation capacities in enterprises.13 
2.2. INNOVATIONS AND TECHNOLOGY IN PHARMACEUTICAL 
INDUSTRY
Investing in innovation is a prerequisite for achieving much-needed advanc-
es in healthcare, as well as in securing the future of the pharmaceutical in-
dustry. There was a perception that research and development departments 
in pharmaceutical companies were no longer innovative and that they were 
not bringing new drugs or products to the market, and that the market was 
replete with an increasing number of similar drugs with the same or similar 
effect that did not show significant progress. Besides, the cost of inventing 
and developing new drugs (cost per launch) has increased dramatically over 
the years.14 Between 1996 and 2003, there was a downward trend in approved 
innovation. During this period, many analysts felt that the pharmaceutical in-
dustry was significantly less innovative compared to the previous period. The 
year 1996 is considered to be an exceptional year in which a large number of 
medicines have been approved, more than in any previous year. Also, during 
10 Jones, G.R.: Organisational Theory, Design and Change. (5. Ed.), Pearson Hall, 2007
11  Mezias S.J., Glynn, M.A.: The Three Faces of Corporate Renewal: Institution, Revolution 
and Evolution, Strategic Management Journal, 14 1993, pp. 77-101.
12  Radas, S., Božić, L.: The antecedents of SME innovativeness in an emerging transition 
economy, Technovation, 29 (6-7) 2009, pp. 438-450.
13  Armbruster, H., Bikfalvi, A., Kinkel, S., Lay, G.: Organizational innovation: The chal-
lenge of measuring non-technical innovation in large-scale surveys, Technovation, 28 (10) 
2008, pp. 644-657.
14  Schmid, E. F., Smith, D. A.: Is pharmaceutical R&D just a game of chance or can strategy 
make a difference?, Drug discovery today, 9 (1) 2004, pp. 18-26.
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the first 10 years after World War II, there was a period of growth in which the 
US pharmaceutical industry showed its dominance. The credit for this growth 
can also be attributed to the Army’s increased need for modern medicines 
during the war. In the first decade of the 21st century, a turning point and a 
turning point in the evolution of the research part of the pharmaceutical and 
biopharmaceutical industries can be observed. The turnaround is partly the 
result of key events of the decade, such as the one that happened on 9/11/2001 
(WTC attack) and US bioterrorist attack in 2002.15 In addition, the emergence 
of H5N1 (bird flu), H1N1 (swine flu), and SARS flu have led to an increased 
need for new solutions, innovations, new drugs to prevent possible catastroph-
ic disasters of this type and endangering human lives.16 As noted above, the 
notion of innovation does not necessarily mean marketing a new product, but 
may also manifest itself by improving marketing access to the market and po-
tential customers. The World Health Organization (WHO) has argued that the 
use of digitization and digital marketing within healthcare organizations and 
pharmaceutical companies is of great importance nowadays as it can greatly 
contribute to the advancement of human health and basic needs. 
3. EMPIRICAL ANALYSIS OF THE INFLUENCE OF INNOVATION 
ON COMPETITIVENESS OF PHARMACEUTICAL 
ENTERPRISES IN THE REPUBLIC OF CROATIA
The empirical research aimed to gain insight and identify the key differences 
that distinguish pharmaceutical companies from their competition and how 
much resources and attention is paid to innovation and technology transfer 
and their direct and indirect impact on business, employees, and the public. 
After selecting the specific companies that make up the theoretical sample in 
this case, in-depth interviews had been structured. This empirical research 
covered pharmaceutical companies in the territory of the Republic of Croatia 
and collected data in the form of an in-depth interview in order to gain insight 
into the propensity to invest in development and innovation, and the impact 
of these same investments on business and employees. The results obtained 
would help to better understand the impact of innovation on people directly 
and indirectly in contact with them and provide an objective basis for under-
15  Preparedness, B.: Public health security and bioterrorism preparedness and response act 
of 2002, Public law, 107 (188) 2002, p. 188.
16  Fontana, J. M., Alexander, E., Salvatore, M.: Translational research in infectious disease: 
current paradigms and challenges ahead, Translational Research, 159 (6) 2012, pp. 430-453.
Intereulaweast, Vol. VII (1) 2020
106
standing and improving the process of innovation implementation if potential 
problems encountered during implementation are considered. 
3.1. SAMPLE AND RESEARCH INSTRUMENT 
Respondents who have represented companies have been in the front office 
for many years. The sample consisted of nine managers/directors. At the be-
ginning of the interview, respondents were guaranteed that confidential com-
pany information would remain secret. Interviews were recorded via audio 
recorders and the elements of the interviews were electronically documented. 
The length of the interviews depended on the time available to the respond-
ents. In order to protect the anonymity of the employees, companies are en-
coded with the characters X1, X2,…, X9. Interviews with respondents were 
conducted over 20-days period (first interview on March 28, and final on April 
17, 2019). Eight representatives interviewed came from foreign-owned enter-
prises, while only one respondent came from a company of Croatian origin. 
The first company tested (X1) is a globally recognized innovation company 
with a long tradition and key competencies in the fields of health and agricul-
ture. It develops new molecules for use in innovative products and solutions 
in the advancement of human, animal, and plant health. The essence of busi-
ness is held by leading positions in growing markets driven by innovation. It 
employs about 80 people in the Republic of Croatia. As a globally innovative 
biopharmaceutical company, the second tested company (X2) pays special 
attention to the discovery, development, and commercialization of innovative 
medicines in important areas of healthcare, such as cardiovascular/metabolic 
health care, cancer, respiratory disease, and inflammatory and autoimmune 
diseases. In 2016, it invested more than $ 5.9 billion in research and develop-
ment worldwide, emphasizing its commitment to finding new drugs that could 
change patients’ lives. With over 100 years of experience, the third-party com-
pany (X3) is a leading manufacturer, innovator, and supplier of fermented 
and semi-synthetic active pharmaceutical substances and a world-renowned 
supplier of Vancomycin and Colistimethate Sodium products. It has increased 
sales in over 70 countries around the world thanks to innovations and over 500 
customers and is continuously developing and expanding its product range to 
meet the needs and provide the best possible service to patients worldwide, 
including Croatia. The next company aims to develop new medicines that help 
patients and provide a better quality of life. The chemical-analytical develop-
ment of new active substances, the development of galenic formulations, and 
clinical trials are particularly emphasized, making the fourth company (X4) 
tested unique in the market, according to representatives. The focal point of 
the research is the development of innovative drugs in the fields of inflam-
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matory diseases and pain, cardiovascular disease, oncology, and viral diseas-
es. Furthermore, unlike those previously examined, the fifth respondent (X5) 
dedicates its business to the protection of animal health and is today a global 
veterinary business dedicated to supporting its customers and their business-
es. Thanks to 60 years of experience, it produces quality medicines and vac-
cines that are on the market worldwide as well as in Croatia. The innovative 
pharmaceutical company, as well as the X6 company, is based on improving 
and extending human life. Their medicines are available in over 150 coun-
tries worldwide. They provide solutions for oncology patients, cardiovascular, 
ophthalmic, respiratory, immunological, and neurological problems. The sev-
enth company (X7) lists the production and sale of generic prescription drugs, 
over-the-counter medicines, and veterinary products as its core business. They 
focus on developing high quality generic value-added medicines that are mar-
keted under their own trademarks. X8, on the other hand, includes a factory 
of medicines, nutritional supplements, and cosmetics. Unlike the others men-
tioned above, it was opened in Vukovar and has three state-of-the-art units: the 
department for the production of semi-solid preparations - creams, ointments 
and gels, the department for the production of non-sterile liquid preparations 
- syrups and liquid food supplements, and the department for the production 
of solid preparations - tablets and capsules. The last company tested (X9) is 
a biopharmaceutical innovation company with over 30,000 employees world-
wide. They aim to provide new solutions for patients with chronic diseases. 
The products of this company can be applied in the fields of oncology, virolo-
gy, immunology, general medicine, and neurology.
4. INTERPRETATION OF RESULTS
4.1. THE KEY INNOVATION
X1 has created a Student Recruitment Application (Spot-one). The manag-
er states that this has proven to be an excellent option for relieving existing 
employees, while on the other hand, it provides an opportunity for students 
of all colleges, who want to earn money, and have obligations at the faculty 
during classical working hours. Enterprise (X2) cites an important internal 
innovation as a new tool for working in the commercial sector (a tool for 
customer segmentation and targeting). With the help of this innovation, cus-
tomers are classified or divided into groups A, B, and C. The most influential 
and largest customers are classified in category A, and it is most important 
for them to maintain frequent contact, visit them frequently and maintain an 
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excellent relationship with them. Such customers are about 15% of the total 
number of customers. Important customers are also classified in category B, 
but they are slightly smaller and not so crucial for maintaining the overall 
business. Customers B account for about 45% of all customers. The rest of the 
buyers are buyers C. Their share in the total sales is quite small, but they are 
important in maintaining the balance, although they are not key to sales as far 
as the survival of the business is concerned. In addition to the introduction of 
similar CRM systems, the third tested company, X3, was the most significant 
innovation in the previous period when it came to the market for vancomycin 
in the form of an infusion solution that has been stable at room temperature 
for a full 16 months, as opposed to the previous 12 to 24 hours. A pharmaceu-
tical composition called “Premixed vancomycin injection in a ready-to-use 
infusion bag” makes it easier to administer an important antibiotic in the treat-
ment of dangerous hospital infections. Company X4 cites the digitalization 
of marketing as a significant innovation of the previous period because until 
now, the channels and methods used to promote products and communicate 
with customers were limited. X5, as an innovator in veterinary medicine, cites 
a significant change in its business operations by expanding its product range 
and improving its key veterinary medicine product to date. As a novelty in 
their company, company X6 cites a revision of a 2015 document that dis-
cusses the postulates and principles of working with patient associations. The 
ambition of this company is to capture the perspective of patients to integrate 
it into their daily work. According to him, things have been standardized in 
the business of the company towards the public, but the innovations that bring 
new therapies to the market have stood out in the previous period. Most prom-
inent from this project was the first migraine prevention drug, CAR-T therapy 
for the treatment of acute lymphoblastic leukemia, B-cells in children, and for 
the treatment of diffuse B-size lymphoma in adults, Luxturn for the treatment 
of children and adults who have lost sight due to inherited distal dystrophies. 
Company X7 is the most prominent manufacturer of two innovative generic 
drugs, namely cancer and pain medicines for musculoskeletal disorders. A key 
benefit of the drug lies in the development of a dispersible imatinib mesylate 
tablet. The tablet has an innovative composition that is made according to an 
independent process patented by this company. Company (X8, as the original 
Croatian company, has developed a SkinAge product line, which is patented 
and created to preserve health and beauty and prevent skin aging and comes 
in the form of a solution, powder, and cream, covering the needs of different 
types of potential customers. Company X9 cites a project called #nemapreda-
ha as the largest project they are working on. The X9 project, in collabora-
tion with the Innovative Pharmaceutical Initiative and other participants, was 
launched to improve the quality of life and cure rates for patients suffering 
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from blood cancer, hemophilia, lung cancer, Alzheimer’s disease, type 1 dia-
betes, migraine, and other bacterial infections. 
4.2. BENEFITS AND CHALLENGES OF IMPLEMENTATION
Enterprise X1 emphasizes the burden on employees and the ability to dele-
gate time-consuming tasks as the biggest asset of this project. On the other 
hand, it gives students who have a lot of obligations in college during the 
workweek the opportunity to make money. New employees are hired to work 
on the said application, working on that application every day and trying to 
make it as day-to-day as possible. They listed increased costs due to increased 
workload and hiring of new employees, as well as overtime realized by the 
existing employees of the company that designed the application. Concerning 
the perception of the general public about X1, they believe that the company is 
paying attention to young people and their employment and education, which 
is certainly a positive element in the corporate image. X2, on the other hand, 
points out that there were a lot of negative moments when implementing the 
CRM system in terms of customization and poor comments on the overall 
situation. They most often came from colleagues of middle or older age be-
cause they did not grow up with computers and IT equipment, such as the 
younger generation, and for them, therefore, this was learning “from scratch”. 
The new system has brought transparency in the performance of tasks and 
requires an up-to-date update of data, which is a problem for someone who 
has not worked that way before. Meetings and training were held for both 
senior and junior colleagues and were supported at all times by colleagues 
from the IT department. As for the overall impression, he states that the result 
is certainly better market connectivity and clearer goals, which at one hand 
has made the job easier and better in the long run. Due to the very nature and 
working atmosphere of company X3, their innovation, they say, left a dis-
tinctly and exclusively positive impression. As the company pays the greatest 
attention to scientists, their personal and professional satisfaction is such a 
great breakthrough, and the hard work and effort they put into making this 
innovation is something they are proud of now. The pursuit of this innova-
tion has provided opportunities and resources for research and development of 
new medicines in Croatia, and our scientists have once again come to the fore. 
Besides, with the FDA’s approval, the motivation to market new innovative 
drugs which they are currently working on has increased. This innovation has 
been a great motivator for the employees to achieve great results in the future, 
for which they are more than capable. In contrast, the situation is different in 
X4. The innovation they implemented caused dissatisfaction with how they 
functioned differently and, according to the managers, felt that the decision 
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was made too soon and went from “nothing” to “everything”. The change was 
not introduced gradually but, as they say, the whole situation was imposed and 
there was an opinion among the employees that they should be asked if they 
wanted this change or not. It is predicted that the X4 business could be better, 
but the adaptation phase, which according to managers, has long seen “worse 
results” as the focus of employees is on adapting to new technologies rather 
than customers, which should be the focus. Also, a dose of talent is needed for 
marketing this type to optimize digitization. Employees felt that this was a bad 
time to make drastic changes, but were forced to adjust to the situation, even 
though a case had occurred where the person left the job. In the case of X5, 
the manager states that they were primarily inclined to think that they were 
entering new unknowns and felt a great deal of uncertainty about the same, but 
after a certain period (1+ years) it turned out that they were indeed given new 
learning opportunities, better positioning of the company. Also, there was, of 
course, greater security in the company as well as greater opportunities for 
career advancement. In terms of finance, innovation has resulted in increased 
profitability and the company has been recognized by the public as an inno-
vator and producer of excellent products. The change and novelty in the case 
of company X6 have brought several positives to its employees, in addition 
to the challenges. The document was presented to employees through discus-
sions with patient associations. Employees had the opportunity through re-
al-life stories and conversations to gain insight into how their work has a daily 
impact and how it will affect human lives and well-being in the future. X6 
is best known among patients’ organizations in 2018, with 1011 out of 1500 
patient groups surveyed claiming to be familiar with X6 and its positive con-
tributions. Besides, this company has become the first company in the world 
to register CAR-T therapy, which has additionally gained a positive reputa-
tion, both in the general and professional public. In addition to the difficulties 
encountered in inventing and patenting innovations, an X7 representative said 
that everything was a trifle given the pride felt within the company after its 
incredible success. He further stated that human resources in their company 
were the key component and the recipe for success and that without excep-
tional and motivated employees, such results would not be possible. Inventive 
and patent-pending product-integrated solutions have enabled this company 
to successfully launch products. Both innovations bring the most benefit to 
end-users - patients. The focus was certainly on the highest quality, safety, and 
better availability. X7 has received numerous awards for the above two inven-
tions. X8, on the other hand, as the original Croatian company with a small 
number of employees, states that they are also extremely proud of the success 
associated with this innovation, but also of all innovations that make one’s life 
easier and better. Besides, for the product from the SkinAge line, they won 
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the Cosmopolitan Beauty Award for 2018 as one of the best innovations in the 
beauty industry. X9 company says the process is challenging in itself because 
the campaign launched raises high expectations from the public and the issue 
is related to an extremely sensitive area. As for the employees themselves, 
participating in such projects is a very emotional and physically difficult pro-
cess, and they must be encouraged and motivated daily. As a company, they 
say, there is a long and difficult road ahead, a large number of overtime hours 
and numerous meetings that addressed the problems they encountered along 
the way. It further states that around 8,000 people in Europe have hemophilia 
B, 60% of whom live with a severe form of the disease. Therapy in the studies 
has shown sufficient results to transform the disease into a milder form. Over 
time, other forms of therapy, such as cancer and infections, could be addressed 
through such forms of therapy, making an immense contribution to society 
and making life easier for those who need it most.
4.3. RESEARCH AND DEVELOPMENT
Regardless of the innovations implemented and the benefits that these inno-
vations have brought, none of the companies tested, except X3 and X8, has 
an R&D department in Croatia. The manager of X2 points out that there is 
certainly more investment in R&D in other countries, as these countries are al-
ways in greater focus both in development and in financial terms. The market 
is bigger, the potential is higher, and more funds go directly to those markets. 
He also states that regulations vary from country to country, as well as the 
amount of money spent at faculties for laboratory and clinical research and in 
youth and science development. In his view, these prospects are still low in 
Croatia, despite the fact that we have great potential. Other companies gener-
ally have global R&D departments and are therefore unable to provide data. 
X3, on the other hand, has a research and development department in Croatia 
and employs as many as 80 scientists of various profiles in the fields of bio-
medical, natural, and biotechnical sciences, mostly educated at Croatian uni-
versities. The director states that there are other locations and countries where 
R&D is performed for the company, but believes that there is no significant 
difference in focus, even on the contrary, R&D in Croatia is increasing year 
by year due to the competence of the researchers. In addition, it states that the 
share of R&D expenses in the company’s revenue is about 10%. The overview 
of key items of in-depth interviews can be seen in table 1.
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5. LIMITATIONS OF RESEARCH
The limitations of this research stem primarily from the definition of the sam-
ple. Interviews were conducted with a small number of companies and for 
this reason, generalization can result in a high degree of bias. However, the 
data obtained can provide a reflection of the pharmaceutical companies’ at-
titudes towards investments and the potential benefits for the employees in 
the context of the labor market and the economic situation in the Republic of 
Croatia. Also, data can serve as a starting point for further analysis and as a 
good benchmark for starting other research on a similar topic. Some of the in-
formation collected through the interviews is considered a trade secret and as 
such could not be presented in the research results, although it contributes to 
a better understanding of the competitive advantage of the company. In order 
to increase the significance of the research results, the sample should include 
a larger number of enterprises within the industry.
6. CONCLUSION
The most important resource, or source of competitive advantage, in addition 
to these innovation projects, is human resources. Employees are considered a 
valuable resource, which can contribute to the profitability and success of the 
business and to the positive reputation of the company. Most companies, when 
implementing innovation, invest in education, training, and additional training 
for their employees. One of the companies, due to the inability to properly 
manage and accept the change, states that an employee has left the workplace. 
It is of utmost importance that the employees have a sufficient amount of sup-
port from the company as well as the opportunity to participate actively in the 
process. In addition to human capital as a source of competitive advantage in 
the company, it is crucial to introduce timely innovation and invest in R&D. 
At the level of the Republic of Croatia, as can be deduced from the research, 
only two of the nine companies surveyed have an R&D department in the 
territory of the country, while other companies, due to the small market and 
insufficient financial and development focus, implement the innovations mod-
eled after the research conducted in other countries. Furthermore, by talking 
to business representatives, one could get the impression that countries with 
head offices outside Croatia are of the opinion that the competencies of sci-
entific staff abroad are at a higher level and that it is, therefore, more cost-ef-
fective to invest in research and development and scientists, not in the terri-
tory of Croatia or the Balkans. However, one of the companies with an R&D 
department in Croatia proves the opposite. Over 80 exceptional and talented 
employees of the Research Laboratory in Zagreb achieve exceptional results 
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and are grateful to the managers of their company for the recognized potential 
and invested resources that enable not only the company to be competitive and 
profitable but also to young scientists who achieve exceptional results to study 
and participate in numerous research, to gain employment opportunities in the 
profession and build on their talent bringing it to a high level. The company as 
such is a positive example that enables young educated people to stay in the 
Republic of Croatia after completing their university education, without the 
need to seek better opportunities to study abroad.
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